{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:12:06Z","timestamp":1777871526675,"version":"3.51.4"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Centro Servizi ANMCO SrL - Societ\u00e0 Benefit"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In recent decades, an incredible evolution in antithrombotic therapies used for treating patients with atherosclerosis, atrial fibrillation, and venous thromboembolism has been observed, leading to the availability of increasingly safe drugs. Nonetheless, bleeding complications remain a significant concern, with considerable health, social, and economic implications. To improve the acute management of patients experiencing or at risk for major bleeding events, specific reversal agents for antithrombotic drugs have been recently developed. While these agents demonstrate effectiveness in small-scale pharmacodynamic studies and clinical trials, it is imperative to balance the benefits of reversing antiplatelet or anticoagulant therapy against the risk of prothrombotic effects. These risks include the potential loss of antithrombotic protection and the prothrombotic tendencies associated with bleeding, major surgery, or trauma. This joint document of the Italian Association of Hospital Cardiologists (Associazione Nazionale Medici Cardiologi Ospedalieri) and the Italian Society of Emergency Medicine (Societ\u00e0 Italiana di Medicina d\u2019Emergenza-Urgenza) delineates the key features and efficacy of available reversal agents. It also provides practical flowcharts to guide their use in patients with active bleeding or those at elevated risk of major bleeding events.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suae033","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T06:22:08Z","timestamp":1715840528000},"page":"ii211-ii220","source":"Crossref","is-referenced-by-count":3,"title":["ANMCO\/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events"],"prefix":"10.1093","volume":"26","author":[{"given":"Leonardo","family":"De Luca","sequence":"first","affiliation":[{"name":"Division of Cardiology, Fondazione IRCCS Policlinico San Matteo , Viale Camillo Golgi 19, 27100 Pavia , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Rocco","family":"Pugliese","sequence":"additional","affiliation":[{"name":"U.O.C. Medicina e Chirurgia d\u2019Accettazione e d\u2019Urgenza, Ospedale Sandro Pertini , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniamino","family":"Susi","sequence":"additional","affiliation":[{"name":"Dipartimento di Emergenza, Policlinico Tor Vergata , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8417-7783","authenticated-orcid":false,"given":"Alessandro","family":"Navazio","sequence":"additional","affiliation":[{"name":"S.O.C. Cardiologia Ospedaliera, Presidio Ospedaliero Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia\u2014IRCCS , Reggio Emilia , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Corda","sequence":"additional","affiliation":[{"name":"S.C. Cardiologia, Azienda Ospedaliera G. Brotzu , Cagliari , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Dipartimento di Emergenza, AUSL Romagna, Presidio Ospedaliero Morgagni-Pierantoni , Forl\u00ec , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-0053","authenticated-orcid":false,"given":"Pietro","family":"Scicchitano","sequence":"additional","affiliation":[{"name":"U.O. Cardiologia-UTIC, Ospedale \u2018F. Perinei\u2019 , Altamura , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Voza","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche, IRCCS Humanitas Research Hospital , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Vanni","sequence":"additional","affiliation":[{"name":"Dipartimento Medicina Sperimentale e Clinica, Universit\u00e0 degli Studi di Firenze, Azienda Ospedaliero-Universitaria Careggi , Florence , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-0579","authenticated-orcid":false,"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[{"name":"U.O.C. Cardiologia, Ospedali dell\u2019Ovest Vicentino, Azienda ULSS 8 Berica , Vicenza , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-8717","authenticated-orcid":false,"given":"Giovanna","family":"Geraci","sequence":"additional","affiliation":[{"name":"U.O.C. Cardiologia, Ospedale Sant\u2019Antonio Abate , Trapani , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Dipartimento Cardio-Toraco-Vascolare, U.O.C. Cardiologia, Azienda Ospedaliera San Camillo Forlanini , Roma , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-8884","authenticated-orcid":false,"given":"Massimo","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"U.O.C. Cardiologia-UTIC, Ospedale Miulli , Acquaviva delle Fonti , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri\u2014ASL Roma 1 , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"De Iaco","sequence":"additional","affiliation":[{"name":"S.C. Medicina di Emergenza-Urgenza, Ospedale Maria Vittoria, ASL Citt\u00e0 di Torino , Turin , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Oliva","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Cure Intensive Cardiologiche, Cardiologia 1-Emodinamica, Dipartimento Cardiotoracovascolare \u2018A. De Gasperis\u2019, ASST Grande Ospedale Metropolitano Niguarda , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2024051606215841200_suae033-B1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","article-title":"Antithrombotic agents","volume":"124","author":"Chan","year":"2019","journal-title":"Circ Res"},{"key":"2024051606215841200_suae033-B2","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"2024051606215841200_suae033-B3","doi-asserted-by":"crossref","first-page":"102025","DOI":"10.1016\/j.cpcardiol.2023.102025","article-title":"Balancing benefits and risks of oral antiplatelet strategies in patients with coronary artery diseases: an evolving issue","volume":"48","author":"De Luca","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2024051606215841200_suae033-B4","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2024051606215841200_suae033-B5","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/eurheartj\/ehad119","article-title":"Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding","volume":"44","author":"Cao","year":"2023","journal-title":"Eur Heart J"},{"key":"2024051606215841200_suae033-B6","first-page":"734","article-title":"Antidoti per le emorragie severe associate agli anticoagulanti orali diretti [Reversal agents for severe bleeding associated with direct oral anticoagulants]","volume":"23","author":"Giubilato","year":"2022","journal-title":"G Ital Cardiol"},{"key":"2024051606215841200_suae033-B7","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/jcm9072318","article-title":"Management of bleeding events associated with antiplatelet therapy: evidence, uncertainties and pitfalls","volume":"9","author":"Godier","year":"2020","journal-title":"J Clin Med"},{"key":"2024051606215841200_suae033-B8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization of platelet reactivity in clopidogrel-treated subjects","volume":"5","author":"Vilahur","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/jth.12058","article-title":"Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation","volume":"11","author":"Zafar","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B10","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"2024051606215841200_suae033-B11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2016.07.017","article-title":"No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents","volume":"15","author":"Zakko","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024051606215841200_suae033-B12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"key":"2024051606215841200_suae033-B13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jama.2021.0135","article-title":"Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial","volume":"325","author":"Ducrocq","year":"2021","journal-title":"JAMA"},{"key":"2024051606215841200_suae033-B14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMc1409373","article-title":"Inefficacy of platelet transfusion to reverse ticagrelor","volume":"372","author":"Godier","year":"2015","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09537104.2015.1035247","article-title":"Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study","volume":"26","author":"Bonhomme","year":"2015","journal-title":"Platelets"},{"key":"2024051606215841200_suae033-B16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/EJA.0000000000000348","article-title":"The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study","volume":"33","author":"Martin","year":"2016","journal-title":"Eur J Anaesthesiol"},{"key":"2024051606215841200_suae033-B17","doi-asserted-by":"crossref","first-page":"e005120","DOI":"10.1161\/CIRCINTERVENTIONS.117.005120","article-title":"Impact of timing on the functional recovery achieved with platelet supplementation after treatment with ticagrelor","volume":"10","author":"Zafar","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"2024051606215841200_suae033-B18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jth.14014","article-title":"Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor","volume":"16","author":"Bertling","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B19","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2015-01-622928","article-title":"Structural and functional characterization of a specific antidote for ticagrelor","volume":"125","author":"Buchanan","year":"2015","journal-title":"Blood"},{"key":"2024051606215841200_suae033-B20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/jth.13680","article-title":"Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin","volume":"15","author":"Pehrsson","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-based ticagrelor reversal agent in healthy volunteers","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B22","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt","year":"2021","journal-title":"NEJM Evid"},{"key":"2024051606215841200_suae033-B23","doi-asserted-by":"crossref","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","article-title":"Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients","volume":"6","author":"Lamberts","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2024051606215841200_suae033-B24","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024051606215841200_suae033-B25","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial","volume":"35","author":"Piccini","year":"2014","journal-title":"Eur Heart J"},{"key":"2024051606215841200_suae033-B26","doi-asserted-by":"crossref","first-page":"j5424","DOI":"10.1136\/bmj.j5424","article-title":"Urgent reversal of vitamin K antagonists","volume":"360","author":"Hunt","year":"2018","journal-title":"BMJ"},{"key":"2024051606215841200_suae033-B27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jemermed.2019.10.011","article-title":"Current strategies for the management of bleeding associated with direct oral anticoagulants and a review of investigational reversal agents","volume":"58","author":"Kaide","year":"2020","journal-title":"J Emerg Med"},{"key":"2024051606215841200_suae033-B28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/rth2.12418","article-title":"Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation","volume":"4","author":"Lu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2024051606215841200_suae033-B29","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/jth.13815","article-title":"Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study","volume":"15","author":"Song","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"2024051606215841200_suae033-B31","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"2024051606215841200_suae033-B32","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/CIRCULATIONAHA.111.081489","article-title":"Reversal of warfarin: case-based practice recommendations","volume":"125","author":"Garcia","year":"2012","journal-title":"Circulation"},{"key":"2024051606215841200_suae033-B33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B34","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"2024051606215841200_suae033-B35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B36","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.118.036710","article-title":"Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding","volume":"139","author":"Van der Wall","year":"2019","journal-title":"Circulation"},{"key":"2024051606215841200_suae033-B37","doi-asserted-by":"crossref","first-page":"1212495","DOI":"10.3389\/fneur.2023.1212495","article-title":"Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists\u2014the RIC-ICH study","volume":"14","author":"Kuklik","year":"2023","journal-title":"Front Neurol"},{"key":"2024051606215841200_suae033-B38","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/a-1704-0630","article-title":"Retrospective analysis of the effectiveness of a reduced dose of idarucizumab in dabigatran reversal","volume":"122","author":"Stone","year":"2022","journal-title":"Thromb Haemost"},{"key":"2024051606215841200_suae033-B39","doi-asserted-by":"crossref","first-page":"e12535","DOI":"10.1002\/rth2.12535","article-title":"Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals","volume":"5","author":"Abdulrehman","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2024051606215841200_suae033-B40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.thromres.2020.11.010","article-title":"Real-world experience with reversal of dabigatran by idarucizumab","volume":"197","author":"Haastrup","year":"2021","journal-title":"Thromb Res"},{"key":"2024051606215841200_suae033-B41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"2024051606215841200_suae033-B42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1060028020943160","article-title":"Andexanet alfa, the possible alternative to protamine for reversal of unfractionated heparin","volume":"55","author":"Maneno","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2024051606215841200_suae033-B43","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B44","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B45","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"2024051606215841200_suae033-B46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/STROKEAHA.121.034572","article-title":"Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care","volume":"53","author":"Huttner","year":"2022","journal-title":"Stroke"},{"key":"2024051606215841200_suae033-B47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate","volume":"56","author":"Sutton","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2024051606215841200_suae033-B48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis","volume":"26","author":"Costa","year":"2022","journal-title":"Crit Care"},{"key":"2024051606215841200_suae033-B49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anti-coagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"2024051606215841200_suae033-B50","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"2024051606215841200_suae033-B52","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur Heart J"},{"key":"2024051606215841200_suae033-B53","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2016003616","article-title":"Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors","volume":"2","author":"Kalathottukaren","year":"2018","journal-title":"Blood Adv"},{"key":"2024051606215841200_suae033-B54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/anae.12910","article-title":"The current place of tranexamic acid in the management of bleeding","volume":"70","author":"Hunt","year":"2015","journal-title":"Anaesthesia"},{"key":"2024051606215841200_suae033-B55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery","volume":"376","author":"Myles","year":"2017","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B56","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa2201171","article-title":"Tranexamic acid in patients undergoing noncardiac surgery","volume":"386","author":"Devereaux","year":"2022","journal-title":"N Engl J Med"},{"key":"2024051606215841200_suae033-B57","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jth.13576","article-title":"Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Desborough","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B59","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/CCM.0000000000002057","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine","volume":"44","author":"Frontera","year":"2016","journal-title":"Crit Care Med"},{"key":"2024051606215841200_suae033-B60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2024051606215841200_suae033-B61","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"2024051606215841200_suae033-B62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"2024051606215841200_suae033-B63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11239-019-01971-1","article-title":"Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition","volume":"50","author":"Dias","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2024051606215841200_suae033-B64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"2024051606215841200_suae033-B65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2024051606215841200_suae033-B66","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.16179","article-title":"International external quality assessment for measurements of direct oral anticoagulants: results and recommendations","volume":"188","author":"Hollestelle","year":"2020","journal-title":"Br J Haematol"},{"key":"2024051606215841200_suae033-B67","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"2024051606215841200_suae033-B68","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology solution set oversight committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024051606215841200_suae033-B69","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024051606215841200_suae033-B70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41569-020-0410-z","article-title":"Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management","volume":"18","author":"Cao","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2024051606215841200_suae033-B71","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_2\/ii211\/57682581\/suae033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/26\/Supplement_2\/ii211\/57682581\/suae033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T06:22:29Z","timestamp":1715840549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/26\/Supplement_2\/ii211\/7674681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":71,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2024,5,16]]},"published-print":{"date-parts":[[2024,5,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae033","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4]]}}}